
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc., a leader in regenerative medicine focused on advanced wound care and surgical markets, is expected to benefit from improving financial performance as net operating profits are projected to rise significantly. The company's valuation is anticipated to improve as it navigates changes in reimbursement structures, particularly with the recently established decisive rates for CY2026. Additionally, despite current market challenges, Organogenesis is well-positioned to capture market share in a consolidating industry, suggesting potential for substantial growth in share value over time.
Bears say
Organogenesis Holdings Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key issues include anticipated lower growth for PuraPly and adverse pricing pressures from Medicare Part B on amniotic products, which may hinder revenue generation. Additionally, the company may struggle with regulatory obstacles affecting market share gains and face challenges related to the uptake of new products and clinical data outcomes, all of which could limit future growth prospects.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares